ATE397457T1 - Stimulierung von t-zellen gegen selbstantigene unter verwendung von ctla-4 inhibierenden wirkstoffen - Google Patents
Stimulierung von t-zellen gegen selbstantigene unter verwendung von ctla-4 inhibierenden wirkstoffenInfo
- Publication number
- ATE397457T1 ATE397457T1 AT99965991T AT99965991T ATE397457T1 AT E397457 T1 ATE397457 T1 AT E397457T1 AT 99965991 T AT99965991 T AT 99965991T AT 99965991 T AT99965991 T AT 99965991T AT E397457 T1 ATE397457 T1 AT E397457T1
- Authority
- AT
- Austria
- Prior art keywords
- ctla
- stimulation
- antigens
- against self
- cells against
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11076198P | 1998-12-03 | 1998-12-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE397457T1 true ATE397457T1 (de) | 2008-06-15 |
Family
ID=22334796
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT99965991T ATE397457T1 (de) | 1998-12-03 | 1999-12-03 | Stimulierung von t-zellen gegen selbstantigene unter verwendung von ctla-4 inhibierenden wirkstoffen |
Country Status (11)
| Country | Link |
|---|---|
| EP (1) | EP1137436B1 (de) |
| JP (1) | JP5341287B2 (de) |
| AT (1) | ATE397457T1 (de) |
| AU (1) | AU774962B2 (de) |
| CA (1) | CA2352783C (de) |
| CY (1) | CY1108318T1 (de) |
| DE (1) | DE69938871D1 (de) |
| DK (1) | DK1137436T3 (de) |
| ES (1) | ES2308857T3 (de) |
| PT (1) | PT1137436E (de) |
| WO (1) | WO2000032231A1 (de) |
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EE05627B1 (et) | 1998-12-23 | 2013-02-15 | Pfizer Inc. | CTLA-4 vastased inimese monoklonaalsed antikehad |
| US7109003B2 (en) | 1998-12-23 | 2006-09-19 | Abgenix, Inc. | Methods for expressing and recovering human monoclonal antibodies to CTLA-4 |
| CN102766210B (zh) | 1999-08-24 | 2015-07-08 | E.R.施贵宝&圣斯有限责任公司 | 人ctla-4抗体及其应用 |
| US7605238B2 (en) | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
| EP1320599A2 (de) | 2000-06-28 | 2003-06-25 | Genetics Institute, LLC | Pd-l2 moleküle: pd-l1 liganden und ihre verwendungen |
| ES2384168T3 (es) | 2002-04-12 | 2012-07-02 | Medarex, Inc. | Procedimientos de tratamiento usando anticuerpos CTLA-4 |
| PT1537878E (pt) | 2002-07-03 | 2010-11-18 | Ono Pharmaceutical Co | Composições de imunopotenciação |
| CN1240436C (zh) * | 2002-08-28 | 2006-02-08 | 上海益众生物技术有限公司 | 成骨生长肽与粒细胞集落刺激因子在造血方面的协同作用 |
| CA2518782A1 (en) * | 2003-03-12 | 2004-09-23 | Duke University | Oligonucleotide mimetics |
| US20040197312A1 (en) * | 2003-04-02 | 2004-10-07 | Marina Moskalenko | Cytokine-expressing cellular vaccine combinations |
| US7494779B2 (en) | 2004-06-14 | 2009-02-24 | Li-Te Chin | Method for producing human antibodies to human CD152 with properties of agonist, antagonist, or inverse agonist |
| PL2161336T5 (pl) | 2005-05-09 | 2017-10-31 | Ono Pharmaceutical Co | Ludzkie przeciwciała monoklonalne przeciwko białku Programmed Death 1 (PD-1) oraz sposoby leczenia raka z zastosowaniem samych przeciwciał anty-PD-1 lub w połączeniu z innymi środkami immunoterapeutycznymi |
| JP2008544746A (ja) | 2005-05-12 | 2008-12-11 | ザイモジェネティクス， インコーポレイテッド | 免疫応答を調節するための組成物および方法 |
| KR101510065B1 (ko) | 2005-06-08 | 2015-04-07 | 다나-파버 캔서 인스티튜트 인크. | 예정 세포사 1(ｐｄ-1) 경로를 억제함으로써 지속 감염 및 암을 치료하기 위한 방법 및 조성물 |
| CA2612241C (en) | 2005-07-01 | 2018-11-06 | Medarex, Inc. | Human monoclonal antibodies to programmed death ligand 1 (pd-l1) |
| CN101325971A (zh) | 2005-12-07 | 2008-12-17 | 米德列斯公司 | Ctla-4抗体剂量递增方案 |
| EP2370593B1 (de) | 2008-11-28 | 2016-03-30 | Emory University | Verfahren zur bestimmung der wirksamkeit von pd-1 antagonisten |
| CN104826106B (zh) | 2009-09-30 | 2019-01-11 | 斯隆凯特林防癌纪念中心 | 用于治疗癌症的组合免疫疗法 |
| EP2488553B1 (de) | 2009-10-12 | 2015-06-17 | Pfizer Inc. | Krebsbehandlung |
| RU2737765C2 (ru) * | 2012-05-04 | 2020-12-02 | Пфайзер Инк. | Простатоассоциированные антигены и иммунотерапевтические схемы на основе вакцин |
| US20150118244A1 (en) | 2012-05-10 | 2015-04-30 | Bristol-Myers Squibb Company | Anti-tumor antibodies as predictive or prognostic biomarkers of efficacy and survival in ipilimumab-treated patients |
| EP3757130A1 (de) | 2013-09-26 | 2020-12-30 | Costim Pharmaceuticals Inc. | Verfahren zur behandlung von blutkrebs |
| KR102171496B1 (ko) | 2013-12-05 | 2020-10-30 | 알에프이엠비 홀딩스, 엘엘씨 | 면역 요법을 위한 보조 메커니즘으로서의 고주파 전기막 파괴(rf-emb)에 의한 암 항원의 항원표출세포로의 개선된 표출 시스템 |
| CA2935423C (en) | 2014-01-24 | 2023-11-07 | Dana-Farber Cancer Institute, Inc. | Antibody molecules to pd-1 and uses thereof |
| AU2015210750B2 (en) | 2014-01-31 | 2020-08-20 | Children's Medical Center Corporation | Antibody molecules to TIM-3 and uses thereof |
| WO2016040882A1 (en) | 2014-09-13 | 2016-03-17 | Novartis Ag | Combination therapies of egfr inhibitors |
| SI3240801T1 (sl) | 2014-12-31 | 2021-04-30 | Checkmate Pharmaceuticals, Inc. | Kombinirana imunoterapija tumorja |
| RS60614B1 (sr) | 2015-03-23 | 2020-08-31 | Jounce Therapeutics Inc | Antitela za icos |
| CA2986765A1 (en) | 2015-05-29 | 2016-12-08 | Agenus Inc. | Anti-ctla-4 antibodies and methods of use thereof |
| ES2878188T3 (es) | 2015-07-29 | 2021-11-18 | Novartis Ag | Terapias de combinación que comprenden moléculas de anticuerpos contra LAG-3 |
| CA2998208A1 (en) | 2015-10-22 | 2017-04-27 | Jounce Therapeutics, Inc. | Gene signatures for determining icos expression |
| US10149887B2 (en) | 2015-10-23 | 2018-12-11 | Canbas Co., Ltd. | Peptides and peptidomimetics in combination with t cell activating and/or checkpoint inhibiting agents for cancer treatment |
| TWI911597B (zh) | 2016-01-15 | 2026-01-11 | 美商Ｒｆｅｍｂ控股有限公司 | 癌症之免疫治療 |
| CN118634323A (zh) | 2016-12-07 | 2024-09-13 | 艾吉纳斯公司 | 抗体和其使用方法 |
| FI3551660T3 (fi) | 2016-12-07 | 2023-12-11 | Agenus Inc | Anti-ctla-4-vasta-aineita ja niiden käyttömenetelmiä |
| MX2019009660A (es) | 2017-02-28 | 2019-10-02 | Bristol Myers Squibb Co | Uso de anticuerpos antigeno 4 del linfocito t (ctla-4) con citotoxicidad celular dependiente de anticuerpos (adcc) mejorada para mejorar la respuesta inmune a una vacuna. |
| EP3752194A4 (de) | 2018-02-13 | 2022-03-16 | Checkmate Pharmaceuticals, Inc. | Zusammensetzungen und verfahren für die tumorimmuntherapie |
| SG11202009647VA (en) | 2018-04-09 | 2020-10-29 | Checkmate Pharmaceuticals | Packaging oligonucleotides into virus-like particles |
| CA3097593A1 (en) | 2018-04-18 | 2019-10-24 | Xencor, Inc. | Pd-1 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and pd-1 antigen binding domains and uses thereof |
| JP7516254B2 (ja) | 2018-04-18 | 2024-07-16 | ゼンコア インコーポレイテッド | Ｉｌ－１５／ｉｌ－１５ｒａヘテロ二量体ｆｃ融合タンパク質およびその使用 |
| US20210236694A1 (en) * | 2018-05-03 | 2021-08-05 | The Johns Hopkins University | Induction of anti-tumoral immune microenvironments |
| SG11202103192RA (en) | 2018-10-03 | 2021-04-29 | Xencor Inc | Il-12 heterodimeric fc-fusion proteins |
| CR20210239A (es) | 2018-10-12 | 2021-12-15 | Xencor Inc | Proteínas de fusión de il-15/il-15ralfa-fc dirigidas a pd-1 y usos de las mismas en terapias combinadas |
| WO2021067863A2 (en) | 2019-10-03 | 2021-04-08 | Xencor, Inc. | Targeted il-12 heterodimeric fc-fusion proteins |
| TW202128757A (zh) | 2019-10-11 | 2021-08-01 | 美商建南德克公司 | 具有改善之特性的 PD-1 標靶 IL-15/IL-15Rα FC 融合蛋白 |
| JP7405361B2 (ja) | 2019-10-21 | 2023-12-26 | 東亞合成株式会社 | 抗腫瘍ペプチドおよびその利用 |
| JP7498889B2 (ja) | 2020-01-30 | 2024-06-13 | 東亞合成株式会社 | Ｃｔｌａ４とｂ７タンパク質との結合を抑制するペプチドおよびその利用 |
| WO2024163477A1 (en) | 2023-01-31 | 2024-08-08 | University Of Rochester | Immune checkpoint blockade therapy for treating staphylococcus aureus infections |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2003455C (en) * | 1988-11-23 | 2000-02-22 | Craig B. Thompson | Immunotherapy involving cd28 stimulation |
| US5811097A (en) * | 1995-07-25 | 1998-09-22 | The Regents Of The University Of California | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
| WO1998042752A1 (en) * | 1997-03-21 | 1998-10-01 | Brigham And Women's Hospital Inc. | Immunotherapeutic ctla-4 binding peptides |
| CN102766210B (zh) * | 1999-08-24 | 2015-07-08 | E.R.施贵宝&圣斯有限责任公司 | 人ctla-4抗体及其应用 |
-
1999
- 1999-12-03 JP JP2000584920A patent/JP5341287B2/ja not_active Expired - Lifetime
- 1999-12-03 DE DE69938871T patent/DE69938871D1/de not_active Expired - Lifetime
- 1999-12-03 CA CA2352783A patent/CA2352783C/en not_active Expired - Lifetime
- 1999-12-03 ES ES99965991T patent/ES2308857T3/es not_active Expired - Lifetime
- 1999-12-03 AT AT99965991T patent/ATE397457T1/de active
- 1999-12-03 WO PCT/US1999/028739 patent/WO2000032231A1/en not_active Ceased
- 1999-12-03 DK DK99965991T patent/DK1137436T3/da active
- 1999-12-03 EP EP99965991A patent/EP1137436B1/de not_active Expired - Lifetime
- 1999-12-03 AU AU21649/00A patent/AU774962B2/en not_active Expired
- 1999-12-03 PT PT99965991T patent/PT1137436E/pt unknown
-
2008
- 2008-09-04 CY CY20081100953T patent/CY1108318T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DK1137436T3 (da) | 2008-10-13 |
| EP1137436A1 (de) | 2001-10-04 |
| ES2308857T3 (es) | 2008-12-01 |
| EP1137436B1 (de) | 2008-06-04 |
| PT1137436E (pt) | 2008-09-15 |
| AU2164900A (en) | 2000-06-19 |
| CA2352783C (en) | 2012-04-10 |
| CY1108318T1 (el) | 2014-02-12 |
| JP2002531416A (ja) | 2002-09-24 |
| DE69938871D1 (de) | 2008-07-17 |
| WO2000032231A1 (en) | 2000-06-08 |
| CA2352783A1 (en) | 2000-06-08 |
| AU774962B2 (en) | 2004-07-15 |
| JP5341287B2 (ja) | 2013-11-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69938871D1 (de) | Stimulierung von T-Zellen gegen Selbstantigene unter Verwendung von CTLA-4 inhibierenden Wirkstoffen | |
| DE69932511D1 (de) | Chimäre rezeptoren | |
| SE9700182D0 (sv) | Implantable heart stimulator | |
| ATE552849T1 (de) | Behandlungsverfahren unter verwendung von ctla-4 antikörpern | |
| ATE239474T1 (de) | Verwendung von levobupivacain | |
| EP1025856A3 (de) | Verfahren zur Modulation von T-Zell Unempfänglichkeit | |
| BR9908082A (pt) | Proteìna de fusão do complexo de histocompatibilidade principal classe ii, conjugado dos domìnios de ligação do complexo de histocompatibilidade principal multimérico, processos para detectar células t tendo uma especificidade do complexo definido de mhc / peptìdeo, para conferir a um indivìduo imunidade adotiva a um complexo definido de mhc / peptìdeo, para estimular ou ativar as células t reativas a um complexo definido de mhc / peptìdeo, para seletivamente matar células t reativas a um complexo definido de mhc / peptìdeo, para tolerizar um indivìduo humano a um complexo definido de mhc / peptìdeo, e, ácido nucleico isolado | |
| DE59611341D1 (de) | Verwendung von saccharid-konjugaten | |
| MD1444B2 (ro) | Metode de inducere a toleranţei celulelor T faţă de un transplant de organe sau ţesuturi | |
| TR200101174T2 (tr) | Migren tedavisi için 5HT1, reseptör agonistleri ve metoklopramid. | |
| CY1106046T1 (el) | Μεθοδος για την θεραπευτικη αγωγη ινωσεως με χρησιμοποιηση ενος ανταγωνιστου της αλφα-4-υπομοναδος της ιντεγκρινης | |
| NO971341D0 (no) | Promoter for reseptor tyrosinkinase TIE | |
| TR199902449T2 (xx) | Farmakolojik etkin maddeler. | |
| DK0952772T3 (da) | Fremgangsmåder til anvendelse af mononukleare phagocytter til at fremme axonal regeneration | |
| EA200100264A1 (ru) | Ангиоцидин: адгезионный рецептор опухолей клетки, специфический для cys-ser-val-thr-cys-gly | |
| GB0102145D0 (en) | Substances | |
| DE69630879D1 (de) | Biologisch abbaubare vorrichtung | |
| DK0768886T3 (da) | Endothelforingseffekter og behandling af vasospastiske lidelser | |
| FR2774916B1 (fr) | Dispositif medical implantable actif, notamment stimulateur cardiaque, defibrillateur et/ou cardioverteur, de type multisite | |
| EE9800315A (et) | Meetod südamepuudulikkuse käitlemiseks endoteliini antagonistide abil | |
| IL131478A0 (en) | Methods for treatment of scar tissue | |
| DE69815822D1 (de) | Verwendung der angiotensin ii-antagonisten losartan und exp-3174 zur behandlung von symptomatisches herzversagen | |
| NO20060637L (no) | Autologe selv-toleranse induserende celler av monocytisk opprinnelse og deres anvendelse i farmasoytiske preparater | |
| DK0970106T3 (da) | uPAR-imiterende peptider | |
| FR2786699B1 (fr) | Medicament destine notamment a prevenir ou traiter les dysfonctions sexuelles |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1137436 Country of ref document: EP |